Endoscopic Mucosal Resection for Early Oesophageal Cancer

Endoscopic mucosal resection (EMR) remains an important organ-preserving treatment for carefully selected superficial oesophageal cancers and high-grade neoplasia. Instead of removing the oesophagus, the technique excises abnormal mucosa through an endoscope, allowing a pathologist to assess the lesion in detail.

The approach is most relevant when disease appears limited to the mucosa, where the risk of lymph-node spread is relatively low. It may be used for squamous cell carcinoma, Barrett’s-related dysplasia and early adenocarcinoma, provided high-quality staging supports local treatment.

Research and debate presented through the International Society for Diseases of the Esophagus have helped clarify how lesion size, morphology, depth and histology influence endoscopic decisions. EMR is best viewed as part of a broader pathway involving diagnosis, staging, pathology and surveillance.

For Australian patients, care is usually coordinated through specialist gastroenterology and upper gastrointestinal cancer services. Major centres in Sydney, Melbourne and Brisbane offer advanced endoscopy, while regional patients may travel to a metropolitan hospital for treatment and multidisciplinary review.

Selecting Patients for Local Treatment

Before EMR, clinicians assess the lesion with high-definition endoscopy, chromoendoscopy or virtual image enhancement. Endoscopic ultrasound may assist selected cases, although it does not replace careful mucosal inspection and tissue assessment. Cross-sectional imaging is considered when there is concern about deeper invasion or nodal disease.

Favourable features include a small, well-demarcated lesion with no signs of submucosal invasion, ulceration or bulky disease. Lesions suspected to have invaded deeply may require surgery, chemoradiotherapy or endoscopic submucosal dissection (ESD) rather than standard resection.

How EMR Is Performed

In cap-assisted EMR, the abnormal area is lifted with an injection and captured within a transparent cap before snare removal. Band-ligation EMR uses suction and a band to create a pseudopolyp that can be safely snared. Both techniques can provide a specimen containing the mucosa and part of the submucosa.

Small lesions may be removed in one piece, known as en bloc resection. Larger areas are often removed piecemeal. This can reduce procedural complexity, but it makes margin interpretation more difficult and may increase the chance of residual or recurrent tissue.

Why Histology Changes the Plan

The resection specimen supplies information that a biopsy alone cannot provide. Pathologists examine the depth of invasion, differentiation, lymphovascular involvement and lateral and deep margins. These findings determine whether the treatment was curative under accepted risk criteria.

A positive deep margin, poorly differentiated cancer or unexpected submucosal invasion may lead to further endoscopic treatment, ESD, surgery or oncology review. The decision is individualised through a multidisciplinary team rather than based on lesion size alone.

EMR Compared With ESD

ESD allows the operator to dissect beneath a lesion and remove a larger area in one piece. This can improve margin assessment and is valuable for lesions with a higher risk of submucosal extension or those that are difficult to remove en bloc with EMR.

EMR is generally faster, widely established and technically less demanding. ESD carries greater procedure time and perforation risk, and its availability is concentrated in expert centres. In Australia, referral from a local gastroenterologist to an advanced endoscopist may be needed when ESD is being considered.

Treating Barrett’s-Related Disease

When early adenocarcinoma or high-grade dysplasia develops in Barrett’s oesophagus, focal EMR can remove visible nodules or irregular areas. Any remaining Barrett’s segment may require eradication therapy, commonly radiofrequency ablation, to reduce the risk of metachronous neoplasia.

Acid suppression and surveillance are important after treatment. Follow-up endoscopy checks the resection site, evaluates residual intestinal metaplasia and detects new lesions. Surveillance intervals depend on pathology, treatment response and the patient’s overall risk profile.

Managing Risks and Recovery

Bleeding, chest discomfort, infection and perforation are recognised complications. Delayed bleeding can occur after the patient has gone home, while extensive circumferential treatment can lead to oesophageal narrowing. Strictures may cause progressive swallowing difficulty and can often be treated with endoscopic dilation.

Patients receive instructions about diet, medications and warning symptoms before discharge. Severe chest pain, vomiting blood, black stools, fever or worsening difficulty swallowing requires urgent medical assessment. Australian hospitals commonly provide an after-hours contact pathway, but emergency services should be used for significant bleeding or breathing problems.

Surveillance After Resection

A clear surveillance plan is essential because local recurrence and new superficial lesions remain possible, particularly in Barrett’s oesophagus or in patients with widespread mucosal abnormalities. Follow-up endoscopy is performed by an experienced operator using enhanced imaging and targeted biopsies where appropriate.

Patients should also address modifiable risks. Stopping tobacco use, limiting alcohol, managing reflux and maintaining a healthy weight may support long-term oesophageal health. In Australia, follow-up can involve public hospital clinics, private specialists and shared care with a general practitioner, depending on location and eligibility.

The 2021 World Congress for Esophageal Diseases highlighted the value of combining technical expertise with consistent pathology and multidisciplinary decision-making. For someone newly diagnosed in Australia, the practical next step is to ask the treating specialist for formal staging and review at an upper gastrointestinal multidisciplinary meeting before selecting EMR, ESD or another treatment.